section name header

Interacting Drugs

OBJECT DRUGS

MAO Inhibitors (nonselective):

MAO-B Inhibitors:

PRECIPITANT DRUGS

Antidepressants, Tricyclic:


Comment:

Linezolid appears to be a weak MAOI, but serotonin syndrome has been reported when it is combined with serotonergic agents such as clomipramine and imipramine. Selective MAO-B inhibitors theoretically should not interact with TCAs, but in some patients MAO-B inhibitors may become nonselective thus increasing the risk of serotonin syndrome. Rasagiline is metabolized by CYP1A2 so theoretically, patients on CYP1A2 inhibitors may be more likely to develop nonselective MAO inhibition due to rasagiline. (For a list of CYP1A2 inhibitors, see CYP450 Table.)


Class 2: Use only if Benefit Felt to Outweigh Risk